The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
Open accessAbstract
Background: Addition of the BCL2 inhibitor venetoclax to lower intensity therapy improved survival in older and unfit patients with newly diagnosed acute myeloid leukemia (AML). The aim of this completed study was to investigate the activity of venetoclax combined with intensive chemotherapy. Methods: In this cohort of a larger phase 2 study we investigated the efficacy and safety of venetoclax plus CLIA in frontline patients with AML and MDS (NCT02115295). Patients ≤ 65 years of age, fit for intensive therapy, received cladribine (5 mg/m2), cytarabine (1.5 g/m2 for <60 and 1 g/m2 for ≥ 60) on days (D) 1-5 and idarubicin (10 mg/m2) on D1-3. Consolidation was cladribine (5 mg/m2) and cytarabine (1 g/m2 for <60 and 0.75 g/m2 for ≥ 60) on D1-3 and idarubicin (8 mg/m2) on D1-2. Venetoclax (400 mg) was given on D2-8 with each course. The primary objective was composite complete response (CR) rate. Secondary objectives were overall response (ORR), duration of response (DOR), event-free survival (EFS), overall survival (OS), and safety. Findings: 50 patients were enrolled. Median age was 48 years (IQR, 37-56). CR+CRi was noted in 47 patients (94%); 37 of 45 (82%) had undetectable measurable residual disease (MRD); 3 patients did not respond, the ORR was 94%. The median DOR, EFS, and OS are not reached. The estimated 12-month DOR, EFS, and OS rate are 72% (95% CI: 58-90%), 68% (95% CI: 54-85%), and 85% (95% CI: 75-97%), respectively. The most common Grade ≥ 3 adverse events were neutropenic fever (n=42), infection (n=6), and ALT elevations (n=6). There was one induction death in a patient treated with CLIA-venetoclax plus a FLT3 inhibitor. Interpretation: Venetoclax added to CLIA was safe and effective in newly diagnosed AML and high risk MDS, producing high rates of durable MRD negative remissions and encouraging EFS and OS across prognostic subgroups. Funding: This trial was supported by M.D. Anderson Cancer Center Leukemia SPORE P50CA100632 and Cancer Center Support Grant P30CA016672.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Self-citationMidostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Cited by
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
Metadata
- Authors
- Kadia, T. M., Reville, P. K., Borthakur, G., Yilmaz, M., Kornblau, S., Alvarado, Y., Dinardo, C. D., Daver, N., Jain, N., Pemmaraju, N., Short, N., Wang, S. A., Tidwell, R. S. S., Islam, R., Konopleva, M., Garcia-Manero, G., Ravandi, F., & Kantarjian, H. M.
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 8
- Issue
- 8
- Pages
- e552-e561
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W3183370518
- Cited by
- 181
- References
- 2
- FWCI
- 16.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. https://app.cochat.ai/papers/10.1016/s2352-3026(21)00192-7
- The paper
- Kadia, T. M., Reville, P. K., Borthakur, G., Yilmaz, M., Kornblau, S., Alvarado, Y., Dinardo, C. D., Daver, N., Jain, N., Pemmaraju, N., Short, N., Wang, S. A., Tidwell, R. S. S., Islam, R., Konopleva, M., Garcia-Manero, G., Ravandi, F., & Kantarjian, H. M. (2021). Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(21)00192-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.